Meribank Biotech Co., Ltd (TPEX:4724)

Taiwan · Delayed Price · Currency is TWD

10.35

+0.15 (1.47%)

Oct 8, 2026, 2:59 PM CST

Market Cap	993.35M -41.8%
Revenue (ttm)	408.48M -16.0%
Net Income	-135.08M
EPS	-1.42
Shares Out	95.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,603
Open	10.20
Previous Close	10.20
Day's Range	9.86 - 10.40
52-Week Range	7.94 - 19.40
Beta	0.43
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Meribank Biotech

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 142

Stock Exchange Taipei Exchange

Ticker Symbol 4724

Full Company Profile

Financial Performance

In 2025, Meribank Biotech's revenue was 471.76 million, an increase of 28.75% compared to the previous year's 366.43 million. Losses were -81.47 million, -13.99% less than in 2024.

Financial Statements